Genentech’s Lucentis BLA Will Not Include Data Supporting Dosing Advantage

This article was originally published in Pharmaceutical Approvals Monthly

15 Sep 2005
News

Pharmaceutical Approvals Monthly

Executive Summary

FDA's decision to deny Genentech fast-track status for Lucentis (ranibizumab) means that the initial submission for the wet age-related macular degeneration therapy, slated for December, will not include data supporting a dosing advantage

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS003036

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS003036

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Genentech’s Lucentis BLA Will Not Include Data Supporting Dosing Advantage

News

Executive Summary

Related Content

Retaane “Approvable” For Macular Degeneration; Alcon Plans July Meeting With FDA

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert